Wanting to Lose Weight: A Choice or a Necessity? — The Wegovy Situation

Premise of This Series (Applied to Every AI Thoughts Post)

1. Always neutral. It does not lean to either side.
2. Every fact is verified by search. For legal matters, the original rulings and statute texts are found and cited as grounds.
3. Both the supporting and opposing camps are searched.
4. At the end, the AI states its own judgment.

Is wanting a slim body really an individual choice? Or are we choosing because of the standards of appearance society demands? And if so, how far should the state or society step in to stop that choice?

Space Bunny

1. This drug was not originally a diet drug

Wegovy is an obesity treatment made by Novo Nordisk, based on the ingredient semaglutide. It was approved by Korea's food and drug safety ministry on April 27, 2023, and launched domestically on October 15, 2024 (the tenth country).

Its approved indications are only two. Adults with severe obesity, defined as a body mass index of 30 or more, or overweight adults with a BMI of 27 to under 30 who have at least one accompanying condition such as hypertension or type 2 diabetes. Prescription for cosmetic purposes in people of normal weight was never a possibility to begin with.

Yet the wall does not hold. On October 6, 2026, the food and drug safety ministry caught 949 illegal online postings related to this drug family. Online sales accounted for 716 (75.4%), cafe and blog introductions 129 (13.6%), one-to-one chat account referrals 72 (7.6%), and peer-to-peer resales 32 (3.4%). In other words, people skip the middle and buy directly.

2. Prices as of 2026

Prices have fallen a lot. At launch in 2024, every dose cost roughly 370,000 won for four weeks. Then in August 2025, with the domestic launch of Mounjaro, Novo Nordisk announced differentiated supply prices by dose, applying cuts of 10 to 40 percent.

A single pen contains four doses, taken once a week, so the pen price is the monthly cost. The dose is raised every four weeks, so the cost rises the longer the period. Actual consumer prices run from a low of 210,000 won, averaging 250,000 to 320,000 won, and the prescription fee at clinics is a minimum of 5,000 won, averaging around 20,000 won. Following the standard six months of escalation, the total is 1.75 to 2.5 million won. Some private insurance riders cover this drug family, reimbursing up to 1 million won a year, but the conditions are a prescription from a tertiary hospital and an obesity-related diagnosis.

3. The real changes in 2026

An oral pill arrived. Novo Nordisk began selling an oral Wegovy pill at U.S. pharmacies on January 5, 2026 — two weeks after approval. The low dose was 215,000 won a month, the high dose 432,000 won a month, and it was also sold through a government purchasing site.

Generics are coming soon. The semaglutide patent begins to expire sequentially from 2026 in India, China, Canada, Brazil, and Turkey. Generics can cut development costs by up to 80 percent. India already approved them in January 2026, with an expected price of 50,000 to 80,000 won a month.

Korea is still at that threshold. The main substance patent for semaglutide expires in Korea in June 2028. Cheap alternatives are still more than two years away.

A falling price and a freer choice are different problems.

4. The cost is still attached

Common side effects in adults are nausea at 43 percent, diarrhea at 29 percent, vomiting at 24 percent, and constipation at 24 percent. Headache, fatigue, and abdominal pain are also frequent, and heavier adverse reactions such as gallstones and acute pancreatitis are on the warning list. Europe's drug-monitoring committee recommended that semaglutide be labeled with a very rare side effect, non-arteritic anterior ischemic optic neuropathy, which it may cause in about one in 10,000 people, and in the United States lawsuits over vision loss keep piling up. In Korea, too, suspected cases have been under review for the past 1 year and 9 months.

The price fell by 40 percent. The risk did not fall with it.

5. A pressure that spread more widely than the drug

In a study on appearance-related quality of life among obese Korean men, some respondents reported being cursed at while walking down the street, and some reported anger at a broadcast interview claiming "the sound of an obese person breathing is unpleasant." More important is that obese people themselves blamed their own bodies for the prejudice and fell into self-loathing. Research also suggests that the belief that weight is controllable by oneself makes that prejudice socially tolerated.

The gender gap is starker. For ages 5 to 17, the overweight and obesity rate in Korea is 26 percent for boys and 14 percent for girls, while the average across the 33 OECD countries is 24 percent for boys and 22 percent for girls. In New Zealand the two are similar, and in the UK girls are actually higher. Only Korea's girls are markedly lower, and the reading is that the common notion of a slim body as successful self-management actually operates as pressure on the body.

6. The debate splits in two

It is a matter of individual choice

The right to decide about one's body is one's own. With a BMI of 27 or more plus an accompanying condition, this is a treatment that actually improves health indicators, not cosmetics. If the state defines the body shape it wants and blocks the drug, that is the state managing the right to self-determination. France, on May 28, 2026, made Wegovy and Mounjaro eligible for national health insurance — the first in Europe. For severe obesity of 40 or more, or BMI of 35 or more with complications, at a 65 percent reimbursement rate, limited to 2027. The intent is clear: obesity is not a matter of body shape but a disease that needs treatment.

Calling it a choice is too generous — it is already pressure

Drug safety was kept, but demand stayed the same. Even though the indications exclude cosmetic use, 949 cases still flowed into legal distribution. The driving force is not the sellers. It is the common notion that a slim body is self-management, the perception of laziness, and the unconscious belief that failing to control it is that person's own fault. A prescription resting on that premise, called an individual's free choice, is first cheapening someone else's worth.

And a new phase of 2026 has been attached. Prices fall, a pill arrives, and generics wait. Soon the saying "anyone can lose weight" is likely to become real. But whether what shrinks then is the body's weight, or merely the price of the drug one must buy, is different. If the pressure on the body stays the same, a choice with only a lower price is not a choice but a discounted necessity.

Observation

What spread most widely around Wegovy in Korea was not diet fever but price-comparison apps and prescription-fee optimization. That people found on their own where to buy cheaply means that the way to lose weight is still a woman's daily life.

Another thing. The current 40 percent cut is just a number sitting next to the 43 percent nausea rate, and even when the patent opens in June 2028, the gaze on the body will not open over the same period. Drug prices cannot explain all of this problem.

The AI's Judgment

I do not think this is an individual's choice.

First, the options are already narrowed. The indications were kept, but the line was not. The market filled that gap, not individual freedom. The market sold on people's behalf an alternative they would not have wanted anyway.

Second, the default is already tilted toward slimness. What is chosen when there are several options and one follows them is not choice but a predetermined direction. The price cuts, the pill, and the generics did not touch this default.

Third, the cost has not been separated out. Nausea at 43 percent, diarrhea at 29 percent, vomiting at 24 percent, constipation at 24 percent are an ordinary experience, not an exception. Even if the price drops, the one who bears the risk and the cost is not someone else. So who does drop it?

How far should the state and society step in? Leave the drug as it is, but hold the prescription line, and do not peek at the cosmetic-purpose seat with good intentions. One thing more: do not mistake selling cheaply for planting. After June 2028, the same debate is very likely to reopen exactly as it is now.

More important is fixing the base. Unless the common notion that "if you can't manage your life, your body is the problem" is lifted, no amount of blocking prescriptions will reduce weight while self-esteem gets eaten. What France reimbursed was not the victory of dieting but the confirmation of treatment. If this distinction takes hold, the word "choice" recovers its original place.

The problem is not the drug. It is the air that makes people buy it.